JP2024503689A - リジニラゾールの固形錠剤剤形 - Google Patents
リジニラゾールの固形錠剤剤形 Download PDFInfo
- Publication number
- JP2024503689A JP2024503689A JP2023542844A JP2023542844A JP2024503689A JP 2024503689 A JP2024503689 A JP 2024503689A JP 2023542844 A JP2023542844 A JP 2023542844A JP 2023542844 A JP2023542844 A JP 2023542844A JP 2024503689 A JP2024503689 A JP 2024503689A
- Authority
- JP
- Japan
- Prior art keywords
- ridinilazole
- tablet
- tetrahydrate
- present
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2100470.0A GB202100470D0 (en) | 2021-01-14 | 2021-01-14 | Solid tablet dosage for of ridinilazole |
| GB2100470.0 | 2021-01-14 | ||
| PCT/IB2022/050311 WO2022153246A1 (en) | 2021-01-14 | 2022-01-14 | Solid tablet dosage form of ridinilazole |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024503689A true JP2024503689A (ja) | 2024-01-26 |
| JP2024503689A5 JP2024503689A5 (https=) | 2026-04-02 |
| JPWO2022153246A5 JPWO2022153246A5 (https=) | 2026-04-02 |
Family
ID=74679044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023542844A Pending JP2024503689A (ja) | 2021-01-14 | 2022-01-14 | リジニラゾールの固形錠剤剤形 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US12318487B2 (https=) |
| EP (1) | EP4277604A1 (https=) |
| JP (1) | JP2024503689A (https=) |
| KR (1) | KR20230131253A (https=) |
| CN (1) | CN116801867A (https=) |
| AU (1) | AU2022207756B2 (https=) |
| CA (1) | CA3145677A1 (https=) |
| GB (1) | GB202100470D0 (https=) |
| IL (1) | IL304354A (https=) |
| MX (1) | MX2023008249A (https=) |
| WO (1) | WO2022153246A1 (https=) |
| ZA (1) | ZA202306739B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023213878A1 (en) * | 2022-05-04 | 2023-11-09 | Summit (Oxford) Limited | Solid tablet dosage form of ridinilazole |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017048217A (ja) * | 2008-12-02 | 2017-03-09 | サミット （オックスフォード） リミテッド | 抗細菌化合物 |
| WO2020017666A1 (en) * | 2018-07-19 | 2020-01-23 | Takeda Pharmaceutical Company Limited | Pharmaceutical compositions with a cdc7 inhibitor |
| JP2020518565A (ja) * | 2017-04-28 | 2020-06-25 | アサナ バイオサイエンシズ，リミティド ライアビリティ カンパニー | アトピー性皮膚炎の治療及び原薬の安定性を向上するための製剤、方法、キット、及び剤形 |
| US20200290995A1 (en) * | 2017-10-05 | 2020-09-17 | Sandoz Ag | Process for the Preparation of Crystalline Ridinilazole Using Acid Addition Salts |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996016042A1 (de) | 1994-11-17 | 1996-05-30 | F. Hoffmann-La Roche Ag | Antibakterielle dibenzimidazol-derivate |
| HUP0303494A3 (en) | 2000-12-15 | 2009-08-28 | Vertex Pharma | Parmaceutical compositions containing bacterial gyrase inhibitors and uses thereof |
| DE60309701T2 (de) | 2002-06-13 | 2007-09-06 | Vertex Pharmaceuticals Inc., Cambridge | 2-ureido-6-heteroaryl-3h-benzoimidazol-4-carbonsäurederivate und verwandte verbindungen als gyrase und/oder topoisomerase iv inhibitoren zur behandlung von bakteriellen infektionen |
| WO2004041209A2 (en) | 2002-11-01 | 2004-05-21 | Paratek Pharmaceuticals, Inc. | Transcription factor modulating compounds and methods of use thereof |
| EP1742637A4 (en) | 2004-04-23 | 2011-06-08 | Paratek Pharm Innc | TRANSCRIPTION FACTOR MODULATION COMPOUNDS AND METHODS OF USE |
| US7825154B2 (en) | 2005-08-12 | 2010-11-02 | The United States Of America As Represented By The Secretary Of The Army | Small molecule inhibitors of botulinum neurotoxins |
| AU2006311729A1 (en) | 2005-11-07 | 2007-05-18 | Vertex Pharmaceuticals Incorporated | Benzimidazole derivatives as gyrase inhibitors |
| GB0612428D0 (en) | 2006-06-22 | 2006-08-02 | Prolysis Ltd | Antibacterial agents |
| CA2563690C (en) | 2006-10-12 | 2014-10-07 | Pharmascience Inc. | Pharmaceutical compositions comprising intra- and extra- granular fractions |
| FR2918566B1 (fr) * | 2007-07-11 | 2009-10-09 | Pierre Fabre Medicament Sa | Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine. |
| EP3315124B1 (en) * | 2009-11-13 | 2021-01-06 | Astrazeneca AB | Bilayer tablet formulations |
| ES2568455T3 (es) | 2010-06-01 | 2016-04-29 | Summit Therapeutics Plc | Compuestos para el tratamiento de enfermedad asociada a Clostridium difficile |
| WO2011151620A1 (en) | 2010-06-01 | 2011-12-08 | Summit Corporation Plc | Compounds for the treatment of clostridium difficile associated disease |
| IL310920A (en) * | 2015-01-27 | 2024-04-01 | Janssen Pharmaceutica Nv | Dispersible compositions |
| KR102737283B1 (ko) | 2019-07-17 | 2024-12-03 | 서밋 (옥스포드) 리미티드 | 리디닐라졸 및 이의 결정 형태의 제조방법 |
-
2021
- 2021-01-14 GB GBGB2100470.0A patent/GB202100470D0/en not_active Ceased
-
2022
- 2022-01-14 CN CN202280010065.7A patent/CN116801867A/zh active Pending
- 2022-01-14 KR KR1020237027498A patent/KR20230131253A/ko active Pending
- 2022-01-14 AU AU2022207756A patent/AU2022207756B2/en active Active
- 2022-01-14 US US17/576,242 patent/US12318487B2/en active Active
- 2022-01-14 EP EP22700441.3A patent/EP4277604A1/en active Pending
- 2022-01-14 MX MX2023008249A patent/MX2023008249A/es unknown
- 2022-01-14 WO PCT/IB2022/050311 patent/WO2022153246A1/en not_active Ceased
- 2022-01-14 JP JP2023542844A patent/JP2024503689A/ja active Pending
- 2022-01-14 CA CA3145677A patent/CA3145677A1/en active Pending
-
2023
- 2023-06-30 ZA ZA2023/06739A patent/ZA202306739B/en unknown
- 2023-07-10 IL IL304354A patent/IL304354A/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017048217A (ja) * | 2008-12-02 | 2017-03-09 | サミット （オックスフォード） リミテッド | 抗細菌化合物 |
| JP2020518565A (ja) * | 2017-04-28 | 2020-06-25 | アサナ バイオサイエンシズ，リミティド ライアビリティ カンパニー | アトピー性皮膚炎の治療及び原薬の安定性を向上するための製剤、方法、キット、及び剤形 |
| US20200290995A1 (en) * | 2017-10-05 | 2020-09-17 | Sandoz Ag | Process for the Preparation of Crystalline Ridinilazole Using Acid Addition Salts |
| WO2020017666A1 (en) * | 2018-07-19 | 2020-01-23 | Takeda Pharmaceutical Company Limited | Pharmaceutical compositions with a cdc7 inhibitor |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022207756A9 (en) | 2024-05-09 |
| CN116801867A (zh) | 2023-09-22 |
| AU2022207756B2 (en) | 2026-01-15 |
| IL304354A (en) | 2023-09-01 |
| MX2023008249A (es) | 2023-07-26 |
| US20220226249A1 (en) | 2022-07-21 |
| AU2022207756A1 (en) | 2023-07-27 |
| ZA202306739B (en) | 2025-05-28 |
| US12318487B2 (en) | 2025-06-03 |
| GB202100470D0 (en) | 2021-03-03 |
| CA3145677A1 (en) | 2022-07-14 |
| EP4277604A1 (en) | 2023-11-22 |
| KR20230131253A (ko) | 2023-09-12 |
| WO2022153246A1 (en) | 2022-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7641320B2 (ja) | ｓＧＣ刺激薬を含んでなる固体分散剤 | |
| JP5632367B2 (ja) | Ｂｉｂｗ２９９２を含有する固形医薬製剤 | |
| KR101931209B1 (ko) | Sglt의 억제제로서 1-(베타-d-글루코피라노실)-2-티에닐-메틸벤젠 유도체를 포함하는 약학 제형 | |
| AU2011316003B2 (en) | Pharmaceutical compositions containing a DGAT1 inhibitor | |
| TWI795344B (zh) | 含藥物之立即釋放錠劑及形成該錠劑的方法 | |
| EA013161B1 (ru) | Дозированная форма для перорального применения | |
| JP2009542647A (ja) | メマンチン医薬組成物 | |
| TW201735928A (zh) | 溶出性優異之口服製劑 | |
| TW201442712A (zh) | 有機化合物之調配物 | |
| EP2165702B1 (en) | Stable and readily dissolved compositions of candesartan cilexetil prepared with wet granulation | |
| US12318487B2 (en) | Solid tablet dosage form of ridinilazole | |
| WO2023213878A1 (en) | Solid tablet dosage form of ridinilazole | |
| CN109963565B (zh) | 一种药物组合物及其制备方法 | |
| WO2024079245A1 (en) | Ridinilazole for treating clostridium difficile | |
| WO2013182609A1 (en) | Stable pharmaceutical compositions with a fast onset | |
| TW202435886A (zh) | 米爾維仙(milvexian)醫藥組合物 | |
| AU2024317636A1 (en) | Pharmaceutical composition containing substituted indol-5-ol derivative and use thereof | |
| WO2022125005A1 (en) | Stable sustained release compositions of acemetacine | |
| WO2019030773A1 (en) | DICLOFENAC COMPOSITIONS WITH LOW DOSE | |
| HK1261747A1 (en) | Solid dispersions comprising a sgc stimulator | |
| HK1261747B (en) | Solid dispersions comprising a sgc stimulator | |
| HK1179859A (en) | Oral dosage forms of bendamustine and therapeutic use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20240930 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241111 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20251111 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260212 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20260325 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20260407 |